drugset
drugset / Trial / NCT05794516

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

NCT05794516 ↗

Phase 1 Completed 40 enrolled Zenas BioPharma (USA), LLC
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of single-ascending doses of ZB004.

Timeline

Start
2023-06-19
Primary completion
2024-03-21
Completion
2024-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ZB004 Unknown — Subcutaneous

Indications

No indication recorded.